ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA-Reference-Cited by-同舟云学术

ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA

Published:2022-05 Issue: Volume:166 Page:112-125
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Remon Jordi^ORCID,Lacas Benjamin,Herbst Roy,Reck Martin^ORCID,Garon Edward B.,Scagliotti Giorgio V.^ORCID,Ramlau Rodryg,Hanna Nasser,Vansteenkiste Johan,Yoh Kiyotaka,Groen Harry J.M.^ORCID,Heymach John V.,Mandrekar Sumithra J.,Okamoto Isamu,Neal Joel W.^ORCID,Heist Rebecca S.,Planchard David,Pignon Jean-Pierre^ORCID,Besse Benjamin,Besse B.,Lacas B.,Pignon J.P.,Remon J.,Berghmans T.,Dahlberg S.,Felip E.,Berghmans Thierry,Besse Benjamin,Dahlberg Suzanne,Felip Enriqueta,Garon Edward,Groen Harry J.M.,Hanna Nasser,Heist Rebecca S.,Herbst Roy,Heymach John V.,Lacas Benjamin,Adjei Alex A.,Heist Rebecca,Mandrekar Sumithra J.,Neal Joel W.,Okamoto Isamu,Pignon Jean-Pierre,Ramlau Rodryg,Remon Jordi,Reck Martin,Scagliotti Giorgio V.,Vansteenkiste Johan,Yoh Kiyotaka

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference56 articles.

1. Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis;Zhan P, Wang J, Lv X jing;J Thorac Oncol Off Publ Int Assoc Study Lung Cancer,2009

2. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges;Fukumura;Nat Rev Clin Oncol,2018

3. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer;Sandler;N Engl J Med,2006

4. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial;Reck;Lancet Oncol,2014

5. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial;Garon;Lancet Lond Engl,2014

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR–Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer;Journal of Clinical Oncology;2024-08-22

2. Future Perspectives in the Second Line Therapeutic Setting for Non-Oncogene Addicted Non-Small-Cell Lung Cancer;Cancers;2023-11-21

3. What to do after immune-checkpoint inhibitors failure in advanced non-small cell lung cancer: an expert opinion and review;Expert Review of Respiratory Medicine;2023-09-02

4. Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives;Lung Cancer;2023-05

5. Current status and future of anti-angiogenic drugs in lung cancer;Clinical and Experimental Medicine;2023-03-15